DIABETIC RETINOPATHY
Carefully designed DR & DME Models.
Diabetic Retinopathy (DR) and Diabetic Macular Edema (DME) are leading causes of vision loss, and are the leading cause of blindness for working age adults. Chronic hyperglycemia triggers a cascade of retinal changes, from microaneurysms and hemorrhages in its early stages to abnormal blood vessel growth, bleeding, and scar tissue formation in its advanced stages.
At PharmaLegacy, we offer a range of in vivo models designed to mimic the key aspects of human diabetic retinopathy. Our models, including the STZ-induced Diabetic Retinopathy model, provide a robust platform for evaluating the efficacy of your novel therapies, providing coverage of the entire range of disease progression and complications such as retinal neovascularization. With diabetic retinopathy models in mice, rats, rabbits, and non-human primates (NHP), PharmaLegacy can meet almost any preclinical need. We offer a full spectrum of services, from diverse drug administration routes to advanced ophthalmic examinations (OCT, FFA, f-ERG) and ex vivo analysis, all within our AAALAC-accredited facilities which have supported hundreds of successful IND filings. Partner with us to gain actionable insights, accelerate your pipeline, and bring new hope to the millions of patients battling diabetic retinopathy.

MODELS / SERVICES
Ensuring superior quality:
- Capacity to house over 30,000 rodents and large animals
- On-site capacity for up to 350 non-human primates, with off-site capacity for up to 30,000 Cynomolgus and Rhesus monkeys
- Electronically managed, traceable research data
- 24/7 access to PharmaLegacy representatives
Choose a CRO that has the tenacity to succeed. Choose PharmaLegacy.
Top Pharmaceutical Companies Trust PharmaLegacy For Their Preclinical Ophthalmology Studies
Your preclinical ophthalmology studies call for flawless and affordable ophthalmology models. Download our Ophthalmology Brochure and see how our models and decades of expertise can give you the clarity you need in your pipeline.

We’re ready when you are.
Tell us your pharmacology challenges and start your DR study in as little as 2 weeks.